MedPath
HSA Approval

CRIXAN TABLET 250 mg

SIN11958P

CRIXAN TABLET 250 mg

CRIXAN TABLET 250 mg

May 25, 2002

RANBAXY (MALAYSIA) SDN. BHD.

RANBAXY (MALAYSIA) SDN. BHD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantRANBAXY (MALAYSIA) SDN. BHD.
Licence HolderRANBAXY (MALAYSIA) SDN. BHD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

J01FA09

clarithromycin

Manufacturer Information

RANBAXY (MALAYSIA) SDN. BHD.

Ranbaxy Malaysia Sdn Bhd

Active Ingredients

CLARITHROMYCIN

250 mg

Clarithromycin

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CRIXAN TABLET 250 mg - HSA Approval | MedPath